BC-1215

Cat. No.:	HY-117937
CAS No.:	1507370-20-8
Molecular Formula:	$C_{26}H_{26}N_4$
Molecular Weight:	394.51
Target:	Ligands for E3 Ligase
Pathway:	PROTAC
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 1 mg/mL (2.53 mM; ultrasonic and warming and heat to 60°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	2.5348 mL	12.6740 mL	25.3479 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 1.25 mg/mL (3.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

BC-1215 is a F-box protein 3 (Fbxo3) inhibitor. BC-1215 works by antagonizing of Fbxo3 on TRAF cytokine signaling and exhibits a low IC_{50} in vitro. BC-1215 can be used for the research of inflammation[1].

IC_{50} & Target

Fbxo3

In Vitro

BC-1215 (0, 0.4, 2, 10, 50 μg/mL; 16 h, 18 h and 24 h) inhibits the Fbxo3-TRAF activation pathway by destabilizing TRAF1-6[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	Murine lung epithellal (MLE) cells, PBMC cells and U937 cells
Concentration:	0, 0.4, 2, 10, 50 μg/mL
Incubation Time:	6 h, 18 h and 24 h
Result:	Decreased TRAF protein and inhibited a broad spectrum of Th1 panel cytokines.

In Vivo

BC-1215 (i.p.; 100 μg) reduces bacterial-induced inflammationa[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Cecal ligation and puncture (CLP)-induced sepsis model[1]
Dosage:	100 μg
Administration:	i.p.
Result:	Significantly attenuated CLP-induced secretion of all three circulating pro-inflammatory cytokines and decreased bacterial counts in the CLP model.

CUSTOMER VALIDATION

- Int J Mol Sci. 2022 Nov 7;23(21):13648.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Chen BB, et al. A combinatorial F box protein directed pathway controls TRAF adaptor stability to regulateinflammation. Nat Immunol. 2013 May;14(5):470-9.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA